Biocon reports a consolidated net profit of Rs. 138.3 crore in Q2FY22
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
The authority also allowed mix and match of booster doses once the primary vaccine has been administered.
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
The WHO chief scientist Soumya Swaminathan tweeted on Oct. 17
U.S. FDA to decide whether to authorize a booster dose in the coming days
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
The test kit uses a reagent developed using Kaneka's molecular testing-related technologies
Subscribe To Our Newsletter & Stay Updated